Company news

VolitionRX Limited news in 2025

VolitionRX Limited's news releases, calls and decks from 2025, newest first.

View company

Volition Issues Business Review 2025

December 17, 2025

Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment

December 11, 2025

Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer

December 8, 2025

VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis

December 4, 2025

VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use

November 25, 2025

VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update

November 13, 2025

VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update

November 10, 2025

Volition Donates Nu.Q® Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs

October 17, 2025

VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants

October 10, 2025

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants

October 9, 2025

Volition Sponsors Upcoming GenomeWeb Webinar

October 2, 2025

Volition Signs Co-Marketing and Services Agreement with Hologic

September 29, 2025

Volition Signs First Human Out Licensing Deal

September 9, 2025

VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update

August 14, 2025

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8, 2025

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025

Calls in 2025

Decks in 2025